Skip to main content

. 1983 Jul 9;287(6385):110–113. doi: 10.1136/bmj.287.6385.110

Anticancer chemotherapy.

P Davey, G R Tudhope

PMCID: PMC1548379 PMID: 6407699

113

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Bakowski M. T. ICRF 159, (+/-) 1,2-di(3,5-dioxopiperazin-1-yl) propane NSC-129,943; razoxane. Cancer Treat Rev. 1976 Jun;3(2):95–107. doi: 10.1016/s0305-7372(76)80007-2. [DOI] [PubMed] [Google Scholar]
Carter S. K. Cancer chemotherapy: new developments and changing concepts. Drugs. 1980 Nov;20(5):375–397. doi: 10.2165/00003495-198020050-00003. [DOI] [PubMed] [Google Scholar]
Goldin A., Chirigos M. A., Macdonald J. S., Fefer A., Mihich E. Biologic-response modifiers and adjuvant chemotherapy: consideration of selected preclinical investigations in relation to clinical potential. Recent Results Cancer Res. 1982;80:351–356. doi: 10.1007/978-3-642-81685-7_57. [DOI] [PubMed] [Google Scholar]
Martin D. S. The scientific basis for adjuvant chemotherapy. Cancer Treat Rev. 1981 Sep;8(3):169–189. doi: 10.1016/s0305-7372(81)80015-1. [DOI] [PubMed] [Google Scholar]
Scheef W., Klein H. O., Brock N., Burkert H., Günther U., Hoefer-Janker H., Mitrenga D., Schnitker J., Voigtmann R. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. Cancer Treat Rep. 1979 Mar;63(3):501–505. [PubMed] [Google Scholar]
Spiegel R. J. The acute toxicities of chemotherapy. Cancer Treat Rev. 1981 Sep;8(3):197–207. doi: 10.1016/s0305-7372(81)80017-5. [DOI] [PubMed] [Google Scholar]
Vogelzang N. J., Raghavan D., Kennedy B. J. VP-16-213 (etoposide): the mandrake root from Issyk-Kul. Am J Med. 1982 Jan;72(1):136–144. doi: 10.1016/0002-9343(82)90600-3. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES